NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Impact of Prevnar 13 on Ear Infections in Children

CompletedN/A

Sponsor: Pfizer

Conditions: Acute Otitis Media, Mastoiditis

Interventions: No intervention

Countries: United States

Prevnar (7 valent pneumococcal conjugate vaccine \[7vPnC\]) has been shown to be effective against ear infections in children. Prevnar 13 is a new vaccine that is similar to Prevnar. It is expected that the effectiveness of Prevnar 13 against ear infections in children will be similar to that observed following Prevnar. Pfizer has committed to conduct a postmarketing study of the impact of Prevnar 13 in reducing ear infections among children.

Eligibility overview

Sex: ALL

Age: 0 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Case eligibility should be based on microbiologic data and should be reviewed and documented by an appropriately qualified member of the investigator's study team before cases are included in the study database.
* S pneumoniae identified from middle ear fluid or mastoiditis sample.
* Specimen obtained from children aged up to 18 years.

Exclusion Criteria:

* As this is an observational, laboratory based database study, there are no exclusion criteria

Locations (8)

Little Rock, Arkansas, United States
Los Angeles, California, United States
San Diego, California, United States
Chicago, Illinois, United States
Winston-Salem, North Carolina, United States
Columbus, Ohio, United States
Pittsburgh, Pennsylvania, United States
Houston, Texas, United States